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OBJECTIVES: The purpose of our analysis was to quan-
tify the cost-effectiveness of monoclonal antibody 17-1A
(MAB) adjuvant therapy versus observation only in pa-
tients with resected Dukes’ C colorectal carcinoma (CRC),
from the perspective of a German third-party payer.
METHODS: This retrospective analysis used the cost-
effectiveness ratios “additional cost for MAB per life-year
gained (LYG)” and “per disease-free year gained (DFYG)”
as target variables and was based on a modeling approach.
Resource use in adjuvant therapy and in treatment of re-
currence was collected from a survey among specialist
health care providers. Costs were determined by multiply-
ing utilized resource items by the price or tariff of each
item. LYG and DFYG after 5 years’ follow-up were ob-
tained from the Kaplan-Meier curves of the original pa-
tient data in the clinical trial, representing a mix of 1.4/1
for colon cancer/rectal cancer. Costs and effectiveness were
discounted by 5% annually.
RESULTS: In the base-case analysis, a scenario of 30%
inpatient and 70% outpatient MAB adjuvant therapy
was applied. There were additional costs for MAB of
11,300 DM per LYG and 11,000 DM per DFYG. In the
sensitivity analysis, the impact of different treatment mo-
dalities was investigated. Exclusive inpatient administra-
tion revealed additional costs for MAB of 470 DM per
LYG and 450 DM per DFYG, whereas exclusive outpa-
tient administration revealed additional costs of 15,940
DM per LYG and 15,520 DM per DFYG. 
CONCLUSIONS: Costs of MAB adjuvant therapy in pa-
tients with CRC are counterbalanced by avoided treat-
ment costs of recurrence to great extents. The additional
cost for MAB per LYG and per DFYG vary considerably
depending on where MAB is administered.
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OBJECTIVES: It has been argued that monoclonal anti-
body 17-1A (MAB) is more effective in colon cancer (CC)
than in colorectal cancer (CRC) Dukes’ C. The purpose
of this analysis was to estimate the cost-effectiveness of
MAB in CC versus observation only from the perspective
of a third-party payer in Germany. 
METHODS: The investigation was based on a subgroup
analysis of original data from patients with CC within the
clinical trial in patients with CRC. The modeling approach
used the cost-effectiveness ratios “additional cost for MAB
per life-year gained (LYG)” and “per disease-free year
gained (DFYG).” LYG and DFYG after 5 years were ob-
tained from the corresponding Kaplan-Meier curves. Re-
lapse prevention with MAB was nearly twice as effective in
CC as in CRC. Economic consequences of resource use,
collected from a survey, were determined by multiplying
utilized items by the prices or tariff of each item. Costs and
effectiveness were discounted by 5% per year.
RESULTS: The base-case analysis revealed additional
cost for MAB of 5,380 DM per LYG and 4,860 DM per
DFYG, when a scenario of 30% inpatient and 70% out-
patient administration was applied. In the sensitivity
analysis, there were net savings of 3,820 DM per LYG
and 3,450 per DFYG in the case of exclusive inpatient
administration and additional cost for MAB up to 9,320
DM per LYG and 8,420 DM per DFYG, when MAB was
administered on an outpatient basis exclusively. 
CONCLUSIONS: MAB is very cost-effective in patients
with CC. In inpatient administration, it results in net sav-
ings for the third-party payer while improving patients’
prognosis at the same time.
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OBJECTIVES: 1) Investigating and comparing the qual-
ity of life of patients with Hodgkin’s Disease (HD) on dif-
ferent dimensions during active treatment and follow-up;
2) identifying longitudinal patterns of QoL dimensions
during re-adaptation to normal life; 3) obtaining cross-
cultural comparisons between the participating countries
and study groups (EORTC and GHSG).
BACKGROUND: Available trials addressed the negative
long-term sequelae in HD survivors, but longitudinal
data—relating the outcome to various treatment-related
variables and to the process of re-adaptation into normal
life after end of treatment—are lacking.
METHODS: Within the randomized EORTC trial H8 for
clinical stage I-II HD, which started in September 1993,
patients receive a QoL questionnaire for completion at
each follow-up visit during the first 5 years after the end
of active therapy. The corresponding HD8: Study of the
GHSG employs the assessment of QoL during and after
active treatment periods. Within both studies the EORTC
QLQ C 30 is used for quality of life assessment incorpo-
rated in the H8/HD8 questionnaire for quality of life in
HD, which addresses, in addition, the aspects of fatigue/
malaise, sexuality, specific side effects, and retrospective
evaluation of treatment.
RESULTS: To date, over 2500 questionnaires of 900 pa-
